Market Closed -
Nasdaq
04:00:00 2024-06-21 pm EDT
5-day change
1st Jan Change
174.8
USD
+2.11%
-1.66%
+40.92%
Presenter SpeechJason Russell;Morgan Stanley;Executive Director (Analysts)Good afternoon, ever...
Krystal Biotech Insider Sold Shares Worth $8,788,062, According to a Recent SEC Filing
Jun. 12
MT
Krystal Biotech Insider Sold Shares Worth $8,788,062, According to a Recent SEC Filing
Jun. 12
MT
Transcript : Krystal Biotech, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:40 AM
Jun. 11
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24
Jun. 10
MT
Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing
May. 23
MT
Transcript : Krystal Biotech, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM
May. 14
Sector Update: Health Care Stocks Gain Pre-Bell Monday
May. 06
MT
Krystal Biotech Swings to Q1 Profit -- Shares Fall
May. 06
MT
Transcript : Krystal Biotech, Inc., Q1 2024 Earnings Call, May 06, 2024
May. 06
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 06
CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Reports Q1 Revenue $45.3M, vs. Street Est of $47.4M
May. 06
MT
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong
May. 06
MT
North American Morning Briefing : Stock Futures -2-
May. 06
DJ
Krystal Biotech, Inc Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
Apr. 22
CI
Stifel Adjusts Price Target on Krystal Biotech to $204 From $178, Maintains Buy Rating
Apr. 16
MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing
Mar. 12
MT
Krystal Biotech Insider Sold Shares Worth $8,547,719, According to a Recent SEC Filing
Mar. 12
MT
Sector Update: Health Care Stocks Ease Late Afternoon
Feb. 26
MT
Sector Update: Health Care Stocks Weaker Monday Afternoon
Feb. 26
MT
Top Midday Gainers
Feb. 26
MT
Krystal Biotech Shares Jump After Surprise Q4 Profit
Feb. 26
MT
Krystal Biotech Swings to Q4 Profit as Company Generates Revenue; Shares Climb Pre-Bell
Feb. 26
MT
Transcript : Krystal Biotech, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Feb. 26
Krystal Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Feb. 26
CI
Earnings Flash (KRYS) KRYSTAL BIOTECH Posts Q4 EPS $0.30, vs. Street Est of $-0.25
Feb. 26
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. It is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include VYJUVEK, KB407, KB408, KB707, KB105, KB104, KB104, and KB301. Its commercial product VYJUVEK is a non-invasive, topical, redo sable gene therapy designed to deliver two copies of theCOL7A1 gene when applied directly to DEB wounds. VYJUVEK is designed to treat DEB at the molecular level by providing the patientâs skin cells the template to make normal COL7 protein, thereby addressing the fundamental disease-causing mechanism. KB407 is developed for the treatment of Cystic Fibrosis. KB408 is developed for the treatment of Alpha-1 Antitrypsin Deficiency. KB707 is developed for the treatment of solid tumors. KB105 is developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis.
More about the company
Last Close Price
174.8
USD
Average target price
189
USD
Spread / Average Target
+8.11%
Consensus
1st Jan change
Capi.
+40.92% 4.99B +15.19% 121B +19.91% 114B +8.24% 23.61B -19.80% 20.43B -16.19% 16.55B -13.45% 16.45B -44.35% 15.59B +66.67% 15.19B +2.13% 13.54B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1